Business Wire

CA-FUJIREBIO

Share
Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer’s disease therapeutics. These new drugs are proving to be major milestones in slowing down disease progression and improving patients’ health. Today’s announcement extends this research program and further refines target analytes, including a pTau217 plasma assay being developed by Beckman Coulter and a Beta Amyloid 1-42 plasma assay being developed by Fujirebio.

These new assays are being developed for use on the recently introduced Beckman Coulter DxI 9000 Immunoassay Analyzer. The DxI 9000 Analyzer’s novel Lumi-Phos PRO Substrate has shown the capability to develop increasingly sensitive and clinically relevant assays.

This agreement leverages Fujirebio’s expertise in the development, manufacturing and regulatory registration of its Neurological Reagent Kits and its expansive Neurological Biomarker menu. Fujirebio has developed a full complement of research use only (RUO) blood-based neurodegenerative biomarkers including β-amyloid1-42, β-amyloid1-40, phospho-Tau181, neurofilament light (NfL), ApoE4, Pan-ApoE and phospho-Tau217.

Kevin O’Reilly, President, Beckman Coulter Diagnostics, commented, “We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the blood stream.”

“Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world,” stated Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. “We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide.”

###

About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products.

Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools.

More information can be found at www.fujirebio.com/neuro.

About Beckman Coulter Diagnostics

A global leader in advanced diagnostics, Beckman Coulter has challenged convention to elevate the diagnostic laboratory’s role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what’s now to what’s next. We seek to accelerate care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Headquartered in Brea, California, with more than 11,000 global team members, Beckman Coulter Diagnostics is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health.

Follow and connect with Beckman Coulter via LinkedIn, X, and Facebook.

©2024 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All other trademarks are the property of their respective owners. 2024-12659

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240312860183/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xsolla Strengthens Game Development Opportunities in the UK With Office Hours at Red Bull Gaming Sphere Partnership10.12.2024 10:00:00 CET | Press release

Xsolla Empowers Indie and Mid-Tier Developers with Payment Solutions and Direct-to-Consumer Opportunities Xsolla, a global video game commerce company, is excited to announce its role as the Official Supporting Partner (Payment Solutions) for Office Hours at Red Bull Gaming Sphere’s December 11th event. This collaborative event, hosted at the Red Bull Gaming Sphere in Shoreditch, London, offers a unique combination of co-working spaces, expert panel discussions, and game showcases to foster new opportunities for developers to grow, learn, and expand their reach in the UK and globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210890933/en/ (Graphic: Xsolla) “We believe in providing equal access to opportunities for everyone and are committed to supporting efforts to help grow the local game development community in the UK,” said Chris Meredith, SVP EMEA at Xsolla. “Through our advanced payment solutions, we aim to em

YANGGUOFU Malatang’s European MALA GALA Debuts in Berlin: Culture as Wings, Fragrance Spreads Worldwide10.12.2024 09:44:00 CET | Press release

The YANGGUOFU Malatang European Spicy Festival, “MALA GALA,” was grandly opened in Berlin on December 5th, accompanied by a comprehensive upgrade of the brand image. With the core concept of “Culture as Wings, Fragrance Spreads Worldwide,” it aims to spread the culture of Eastern cuisine overseas. Since the first store was established in Spain in 2023, YANGGUOFU has quickly opened branches in 10 European countries, winning widespread acclaim. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241206278177/en/ MALA GALA (Photo: Business Wire) The MALA GALA marks the brand’s deep expansion into the European market with the simultaneous opening of new stores in Berlin and Prague. Moving forward, new stores in five countries and ten cities will be linked, and the brand’s sixth-generation stores will officially debut across the European continent, from the UK, France, Germany, and Italy to the Czech Republic. To deepen cultural excha

AQEMIA Hits $100 Million Funding Milestone, Paving Way to Clinical Trials and Global Expansion Starting with London, UK10.12.2024 09:29:00 CET | Press release

AQEMIA, a pioneering techbio that teaches atomic scale physics to a generative AI to invent innovative medicines, announces two major milestones: $100 million in cumulative funding and the beginning of a global expansion starting with London (United Kingdom). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210380168/en/ Maximilien Levesque, CEO and Cofounder of AQEMIA (left) and Emmanuelle Martiano Rolland, COO and Cofounder of AQEMIA (Photo: Business Wire) The new $38 million funding round, led by new investor Cathay Innovation, brings total funds raised since inception to over $100 million. This round, coming less than a year after the previous one, follows the successful validation of AQEMIA’s drug discovery platform through outstanding results in internal preclinical programs and pharmaceutical partnerships, particularly in oncology. The funding will support AQEMIA’s development goals, including preparations for clinic

Kioxia Develops OCTRAM (Oxide-Semiconductor Channel Transistor DRAM) Technology10.12.2024 09:22:00 CET | Press release

Kioxia Corporation, a world leader in memory solutions, today announced the development of OCTRAM (Oxide-Semiconductor Channel Transistor DRAM), a new type of 4F2 DRAM, comprised of an oxide-semiconductor transistor that has a high ON current, and an ultra-low OFF current, simultaneously. This technology is expected to realize a low power DRAM by bringing out the ultra-low leakage property of the InGaZnO*1 transistor. This was first announced at the IEEE International Electron Devices Meeting (IEDM) held in San Francisco, CA on December 9, 2024. This achievement was jointly developed by Nanya Technology and Kioxia Corporation. This technology has the potential to lower power consumption in a wide range of applications, including AI and post-5G communication systems, and IoT products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209099702/en/ Fig.1: Cross-sectional TEM image for the InGaZnO vertical transistor (Photo: Bu

FINEOS ranked in Top Ten of Everest Group’s Leading 50™ Life & Annuity (L&A) Insurance Technology Providers report10.12.2024 09:00:00 CET | Press release

FINEOS Corporation (ASX:FCL) today announced that Everest Group’s Leading 50TM Life & Annuity (L&A) Insurance Technology Providers report has positioned FINEOS as a leader in the global life, accident and health insurance technology market for 2024. To determine its rankings, Everest Group began with over 200 technology providers serving the broad spectrum of the L&A insurance, retirements, and pensions industry and narrowed the list down based on the assessed company’s revenues, line of business (LoB) coverage, value-chain coverage and client geographic coverage. Ultimately, the renowned research firm arrived at the Leading 50TM Life & Annuity (L&A) Insurance Technology Providers 2024, with FINEOS well-positioned as a result of its scale of operations, scope, technology and innovation, delivery footprint, and buyer satisfaction, in addition to revenue, number of clients and year-over-year growth, all evidenced by previous Everest Group research. Michael Kelly, FINEOS CEO, said, “We ar

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye